Sanofi Target IP definition

Sanofi Target IP means ************************************.
Sample 1
Sanofi Target IP means only those claims in Patent Rights within the Sanofi Patent Rights in existence on the termination of the Discovery Program, including the Tail Period, which would be infringed by the making, using, developing, selling, or importing of (a) any Licensed Refused Sanofi Candidate (*************************), (b) any Sanofi Divested Antibody (*******************************), (c) any Failed MTC as referred to in Section 2.11(c) or ***************** as referred to in Section 2.11(b), (d) any Sanofi Regulatory Divested Antibody (**********************************), (e) in the case of Section 12.8, any Antibody (including any MTC) discovered in the Discovery Program against a Program Target (******************************), or(f) any MTC (and, if applicable, any other Antibody) referred to in Section 12.11(b) (*****************************), as the case may be. For the avoidance of doubt, the parenthetical references in (a), (b), (d), (e), and (f) above are included to limit the Patent Rights ************************** to only those Patent Rights that would ******************************. These parenthetical references do not limit other Patent Rights included in this definition. “Sole Inventions” shall have the meaning set forth in Section 6.1(a). “Solely Developed Immunoconjugate” shall have the meaning set forth in Section 2.11(b). “Special JRC Meeting” shall have the meaning set forth in Section 2.4(a). “Stock Purchase Agreement” shall mean the Stock Purchase dated as of the Original Agreement Effective Date by and between (a) Sanofi, sanofi-aventis US LLC, and Sanofi-Aventis Amerique du Nord and (b) Regeneron. “Tail Period” shall have the meaning set forth in Section 2.9. “Target” shall mean any gene, receptor, ligand, or other molecule (a) potentially associated with a disease activity, and (b) which potentially has a biological activity that is modified by direct interaction with an Antibody, including any MTC, or (c) to which an Antibody, including any MTC, binds, ***********************************. “Target Discovery Plan” shall have the meaning set forth in Section 2.3. “Target List” shall mean the list of Targets on the Rolling Target List and the Immunized Target List, but excluding Excluded Targets. “Term” shall have the meaning set forth in Section 12.1. “Territory” shall mean all the countries and territories of the world. “Third Party” shall mean any Person other than Sanofi or Regeneron or any Affiliate of either Party. “Third Party Opportu...
Sample 1
Sanofi Target IP means only those claims in Patent Rights within the Sanofi Patent Rights in existence on the termination of the Discovery Program, including the Tail Period, which would be infringed by the making, using, developing, selling, or importing of (a) any Licensed Refused Sanofi Candidate (*************************), (b) any Sanofi Divested Antibody (*******************************), (c) any Failed MTC as referred to in Section 2.11(c) or ***************** as referred to in Section 2.11(b), (d) any Sanofi Regulatory Divested Antibody (**********************************), (e) in the case of Section 12.8, any Antibody (including any MTC) discovered in the Discovery Program against a Program Target (******************************), or(f) any MTC (and, if applicable, any other Antibody) referred to in Section 12.11(b) (*****************************), as the case may be. For the avoidance of doubt, the parenthetical references in (a), (b), (d), (e), and (f) above are included to limit the Patent Rights ************************** to only those Patent Rights that would ******************************. These parenthetical references do not limit other Patent Rights included in this definition. “Sole Inventions” shall have the meaning set forth in Section 6.1(a).
Sample 1

Examples of Sanofi Target IP in a sentence

  • The royalties payable under Sections 4.5 (ii), 4.5 (iv), 4.5(vi), and 4.5(vii) of this Agreement shall each be paid on a Royalty Product-by-Royalty Product and country-by-country basis, commencing on the Effective Date and ending on the expiration of the last to expire Valid Claim of the licensed Sanofi Target IP (the applicable period of time during which royalties are payable pursuant to this sentence and the preceding sentence being referred to as the applicable “Royalty Term”).

  • With respect to any Failed MTC each Party hereby grants to the other a non-transferable, non-exclusive, worldwide, royalty-bearing (in accordance with Section 4.4 herein) license, with the right to sublicense, and with respect to Regeneron Target IP and Sanofi Target IP (as the case may be) solely to make, have made, use, sell, offer to sell and import IFMs. For the avoidance of doubt, such a license shall not include rights to any underlying Immunoconjugate technology owned by the licensing Party.

  • The royalties payable under Sections 4.5 (i), 4.5(iii), and 4.5(v) of this Agreement shall each be paid for the period of time, as determined on a Royalty Product-by-Royalty Product and country-by-country basis, commencing on the Effective Date and ending on the later to occur of (a) ***********************, (b) the expiration of the last to expire Valid Claim of the Licensed Sanofi Target IP or Regeneron Target IP, as the case may be.

  • The royalties payable under Sections 4.4 (ii), 4.4 (iii), and 4.4(vi) of this Agreement shall each be paid on a Royalty Product-by-Royalty Product and country-by-country basis, commencing on the Effective Date and ending on the expiration of the last to expire Valid Claim of the licensed Sanofi Target IP (the applicable period of time during which royalties are payable pursuant to this sentence and the preceding sentence being referred to as the applicable “Royalty Term”).

  • Royalty payments for Antibodies referred to and described in Section 12.11(b) of ************ in such countries where, and for so long as, its manufacture, use or sale is covered by a Valid Claim in any Sanofi Target IP as determined on a country-by- country basis.

  • Royalty payments for a Sanofi Regulatory Divested Antibody of *********** in such countries where, and for so long as, its manufacture, use or sale is covered by a Valid Claim in any Sanofi Target IP as determined on a country-by-country-basis.

  • The royalties payable under Sections 4.5 (i), 4.5(iii), and 4.5(v) of this Agreement shall each be paid for the period of time, as determined on a Royalty Product-by-Royalty Product and country-by-country basis, commencing on the Effective Date and ending on the later to occur of (a) ****************, (b) the expiration of the last to expire Valid Claim of the Licensed Sanofi Target IP or Regeneron Target IP, as the case may be.

  • The royalties payable under Sections 4.4 (i), 4.4(iv), and 4.4(v) of this Agreement shall each be paid for the period of time, as determined on a Royalty Product-by-Royalty Product and country-by-country basis, commencing on the Effective Date and ending on the later to occur of (a) ************************ and, if applicable, (b) the expiration of the last to expire Valid Claim of the Licensed Sanofi Target IP or Regeneron Target IP, as the case may be.

Related to Sanofi Target IP

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Collaboration IP means Collaboration Know-How and Collaboration Patents.

  • Collaboration Patent Rights means Patent Rights claiming Collaboration Know-How.

  • Licensed Compound means [***].

  • Licensed Compounds means any EZH2 Compound(s) that is:

  • Program Patent Rights means any Patent Rights that contain one or more claims that cover Program Inventions.

  • Licensed Patent Rights means:

  • Program Technology means Program Know-How and Program Patents.

  • ISIS means the department’s individualized services information system.

  • GSK will have the meaning set forth in the Preamble.

  • Collaboration Patents means any and all Patents that claim or cover any of the Collaboration Know-How.

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • Joint Patent Rights means Patent Rights that contain one or more claims that cover Joint Technology.

  • Developed IP means any Intellectual Property Rights that are conceived or reduced to practice, or otherwise created or developed, by or on behalf of a Party, its Affiliates or sublicensees, alone or together with one or more Third Parties, during the Term in connection with the Development, Manufacture, or use of the Compound or any Product.

  • Licensee Technology means the Licensee Know-How and Licensee Patents.

  • Third Party Technology means all Intellectual Property and products owned by third parties and licensed pursuant to Third Party Licenses.

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Research Program Term has the meaning set forth in Section 2.2.

  • BMS means the Company, all related companies, affiliates, subsidiaries, parents, successors, assigns and all organizations acquired by the foregoing.

  • Assigned Patent Rights means all of the following, whether now owned or hereafter acquired or arising:

  • Collaboration Know-How means all Know-How conceived, discovered, developed or otherwise made by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing (solely or jointly by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing) in the course of [***].

  • Licensor Technology means the Licensor Patents and the Licensor Know-How.

  • Licensed IP means the Licensed Patents and the Licensed Know-How.

  • Product Technology means the Product Know-How and Product Patents.

  • Patent Rights means the rights and interests in and to issued patents and pending patent applications (which, for purposes of this Agreement, include certificates of invention, applications for certificates of invention and priority rights) in any country or region, including all provisional applications, substitutions, continuations, continuations-in-part, divisions, renewals, all letters patent granted thereon, and all reissues, re-examinations and extensions thereof, and all foreign counterparts of any of the foregoing.